COVID Vaccine Sputnik V Manufacturing Stock Hits Upper Circuit Today, FIIs Increase Stake in Q1 – Stock Delivered Multibagger Return in Just 1 Month!
The company’s shares have delivered a multibagger return of over 140 per cent to its shareholders in just 6 months.
Incorporated in 1984, Panacea Biotec Ltd is a Small-Cap research-based biotechnology company based in India. The company specializes in research, development, manufacturing, and marketing of branded vaccines, pharmaceutical formulations, nutraceuticals, and food and nutrition products for both domestic and international markets. Its operations are divided into two main segments: vaccines and formulations. Notably, Panacea Biotec has expertise in developing fully liquid combination vaccines that can be stored at 2-8°C.
In 2021, Panacea Biotec Ltd signed an agreement with the Russian Direct Investment Fund (RDIF) to manufacture 100 million doses per year of Sputnik V, the world’s first registered COVID-19 vaccine.
DSIJ's ‘Penny Pick’ service provides research-backed penny stock recommendations below Rs. 100. If this interests you, do download the service details here.
At the start of the day's trading session, shares of Panacea Biotec Ltd opened at Rs 310 per share, compared to the previous day's closing figure of Rs 302.76 per share on the NSE. Currently, the shares are at Rs 317.89 per share. The stock has rallied 5 per cent today and hit the upper circuit, reflecting strong demand in the market. The company's current market capitalization stands at Rs 1,947 crore. Additionally, the company’s shares have delivered a 100 per cent multibagger return in just 1 month.
As per the Quarterly Results, in the Q1 FY25, Panacea Biotec Ltd recorded a revenue of Rs 116 crore compared to Rs 129 crore. The operating loss stood at Rs 14 crore. The net loss stood at Rs 16 crore compared to a profit of Rs 11 crore. Looking at the annual performance, the company generated a revenue of Rs 559 crore in FY24. The operating loss for FY24 was Rs 20 crore with a net loss of Rs 2 crore compared to a net loss of Rs 34 crore in FY23.
According to the shareholding pattern of the company, the promoters hold a significant 73.47 per cent stake. Public investors own 25.21 per cent of the shares, while Foreign Institutional Investors (FIIs) hold 0.26 per cent and Domestic Institutional Investors (DIIs) own 1.07 per cent.
Check out my recent article here.
Disclaimer: The article is for informational purposes only and not investment advice.